Altimmune says ‘something raised attention of FDA’
The Fly

Altimmune says ‘something raised attention of FDA’

At the Guggenheim Securities Healthcare Innovation Conference, Altimunne said “They mentioned in a recent publication that glucagon could have cardiotoxic effects So this is a reasonable study to do.” The company speculated that there might be something there that “raised the attention of the (FDA). We don’t know for certain.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App